14 February 2023: Database Analysis
Association Between Neutrophil-Lymphocyte Ratio and All-Cause Mortality in Critically Ill Patients with Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study
Shujie Hao 1ABCDEF , Yamei Yuan 1BDEG , Weidong Ye 2BCD , Xiangming Fang 2AEFG*DOI: 10.12659/MSM.938554
Med Sci Monit 2023; 29:e938554
Table 3 Subgroup analysis of the associations between mortality and the neutrophil-lymphocyte ratio.
| Characteristic | N | NLR of 28-day mortality | ||||
|---|---|---|---|---|---|---|
| Q 1 | Q 2 | Q 3 | Q4 | P for interaction | ||
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||
| Age | 0.996 | |||||
| 1590 | 1 (Ref) | 1.62 (0.93~2.81) | 1.79 (1.04~3.1) | 2.00 (1.15~3.47) | ||
| ≥75 | 1060 | 1 (Ref) | 1.46 (0.86~2.48) | 1.74 (1.05~2.91) | 1.78 (1.07~2.95) | |
| Gender | 0.055 | |||||
| Female | 1227 | 1 (Ref) | 2.26 (1.24~4.12) | 1.81 (1~3.28) | 2.71 (1.53~4.8) | |
| Male | 1423 | 1 (Ref) | 1.13 (0.68~1.87) | 1.60 (0.99~2.59) | 1.45 (0.88~2.38) | |
| Ethnicity | 0.152 | |||||
| White | 1889 | 1 (Ref) | 1.32 (0.83~2.12) | 1.51 (0.95~2.39) | 1.58 (1~2.51) | |
| Non-white | 433 | 1 (Ref) | 2.54 (1.03~6.27) | 3.40 (1.34~8.6) | 2.24 (0.83~6.04) | |
| Other | 328 | 1 (Ref) | 1.10 (0.38~3.22) | 1.66 (0.6~4.57) | 3.16 (1.11~9) | |
| MBP | ||||||
| 1172 | 1 (Ref) | 1.15 (0.7~1.9) | 1.10 (0.69~1.76) | 1.50 (0.95~2.38) | 0.103 | |
| ≥75 | 1478 | 1 (Ref) | 2.40 (1.3~4.45) | 3.37 (1.83~6.2) | 3.10 (1.66~5.81) | |
| Malignant cancer | 0.4 | |||||
| Yes | 393 | 1 (Ref) | 0.57 (0.25~1.31) | 0.91 (0.42~1.96) | 0.83 (0.41~1.68) | |
| No | 2257 | 1 (Ref) | 1.89 (1.22~2.94) | 2.29 (1.48~3.55) | 2.63 (1.69~4.1) | |
| Congestive heart failure | 0.741 | |||||
| Yes | 1401 | 1 (Ref) | 1.43 (0.86~2.36) | 1.78 (1.08~2.93) | 2.13 (1.31~3.45) | |
| No | 1249 | 1 (Ref) | 1.54 (0.86~2.76) | 1.79 (1.03~3.1) | 2.01 (1.14~3.54) | |
| Diabetes | 0.173 | |||||
| Yes | 1024 | 1 (Ref) | 1.15 (0.65~2.02) | 1.35 (0.81~2.27) | 1.91 (1.11~3.29) | |
| No | 1626 | 1 (Ref) | 2.11 (1.24~3.59) | 2.42 (1.42~4.13) | 2.50 (1.47~4.26) | |
| Hypertension | 0.235 | |||||
| Yes | 841 | 1 (Ref) | 2.86 (1.2~6.8) | 2.37 (0.96~5.83) | 3.79 (1.55~9.24) | |
| No | 1809 | 1 (Ref) | 1.25 (0.81~1.91) | 1.55 (1.04~2.32) | 1.62 (1.07~2.43) | |
| Renal disease | 0.486 | |||||
| Yes | 847 | 1 (Ref) | 1.06 (0.57~1.98) | 1.31 (0.72~2.38) | 1.14 (0.63~2.06) | |
| No | 1803 | 1 (Ref) | 1.90 (1.17~3.07) | 1.95 (1.21~3.12) | 2.62 (1.62~4.23) | |
| Liver disease | 0.056 | |||||
| Yes | 327 | 1 (Ref) | 1.28 (0.52~3.17) | 1.57 (0.65~3.76) | 1.27 (0.53~3.04) | |
| No | 2323 | 1 (Ref) | 1.71 (1.12~2.61) | 1.88 (1.24~2.85) | 2.41 (1.59~3.63) | |
| HRs were adjusted for age; sex; race; diabetes; hypertension; liver disease; renal disease; malignant cancer; platelets; WBC; anion gap; bicarbonate; BUN; chloride; creatinine; potassium; lactate; heart rate; mbp; respiratory rate; temperature; spo2; glucose; sofa; sapsii. | ||||||
| Characteristic | N | NLR of in-hospital mortality | ||||
| Q 1 | Q 2 | Q 3 | Q4 | P for interaction | ||
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||
| Age | 0.945 | |||||
| 1590 | 1 (Ref) | 1.63 (0.97~2.73) | 1.84 (1.11~3.05) | 1.99 (1.21~3.29) | ||
| ≥75 | 1060 | 1 (Ref) | 1.26 (0.75~2.12) | 1.57 (0.95~2.58) | 1.57 (0.96~2.57) | |
| Gender | 0.045 | |||||
| Female | 1227 | 1 (Ref) | 2.32 (1.28~4.22) | 2.07 (1.15~3.73) | 2.78 (1.57~4.91) | |
| Male | 1423 | 1 (Ref) | 1.05 (0.65~1.68) | 1.42 (0.91~2.21) | 1.31 (0.84~2.05) | |
| Ethnicity | 0.316 | |||||
| White | 1889 | 1 (Ref) | 1.15 (0.73~1.8) | 1.39 (0.9~2.15) | 1.46 (0.96~2.23) | |
| Non-white | 433 | 1 (Ref) | 2.92 (1.19~7.11) | 2.83 (1.09~7.35) | 1.99 (0.75~5.26) | |
| Other | 328 | 1 (Ref) | 1.31 (0.49~3.47) | 1.92 (0.75~4.9) | 2.85 (1.07~7.62) | |
| MBP | 0.045 | |||||
| 1172 | 1 (Ref) | 1.07 (0.66~1.72) | 1.04 (0.67~1.63) | 1.39 (0.91~2.12) | ||
| ≥75 | 1478 | 1 (Ref) | 2.56 (1.41~4.66) | 3.61 (1.99~6.54) | 3.55 (1.93~6.55) | |
| Malignant cancer | 0.082 | |||||
| Yes | 393 | 1 (Ref) | 0.45 (0.2~1.01) | 1.22 (0.61~2.45) | 0.86 (0.46~1.62) | |
| No | 2257 | 1 (Ref) | 2.17 (1.39~3.39) | 2.55 (1.64~3.98) | 3.14 (2.01~4.9) | |
| Congestive heart failure | 0.617 | |||||
| Yes | 1401 | 1 (Ref) | 1.37 (0.85~2.21) | 1.59 (0.99~2.56) | 2.01 (1.27~3.17) | |
| No | 1249 | 1 (Ref) | 1.61 (0.91~2.85) | 2.00 (1.17~3.43) | 2.21 (1.27~3.84) | |
| Diabetes | 0.118 | |||||
| Yes | 1024 | 1 (Ref) | 1.08 (0.63~1.85) | 1.21 (0.73~1.99) | 1.9 (1.13~3.18) | |
| No | 1626 | 1 (Ref) | 1.95 (1.17~3.24) | 2.19 (1.33~3.63) | 2.18 (1.33~3.57) | |
| Hypertension | 0.098 | |||||
| Yes | 841 | 1 (Ref) | 3.36 (1.4~8.04) | 2.74 (1.12~6.7) | 4.43 (1.87~10.5) | |
| No | 1809 | 1 (Ref) | 1.23 (0.82~1.84) | 1.55 (1.05~2.28) | 1.61 (1.1~2.37) | |
| Renal disease | 0.481 | |||||
| Yes | 847 | 1 (Ref) | 1.04 (0.56~1.96) | 1.37 (0.76~2.49) | 1.22 (0.68~2.19) | |
| No | 1803 | 1 (Ref) | 1.79 (1.14~2.81) | 1.75 (1.13~2.72) | 2.31 (1.5~3.56) | |
| Liver disease | 0.029 | |||||
| Yes | 327 | 1 (Ref) | 1.22 (0.52~2.83) | 1.47 (0.64~3.39) | 1.15 (0.5~2.64) | |
| No | 2323 | 1 (Ref) | 1.69 (1.12~2.54) | 1.84 (1.24~2.73) | 2.26 (1.54~3.32) | |
| HRs were adjusted for age; sex; race; diabetes; hypertension; liver disease; renal disease; malignant cancer; platelets; WBC; anion gap; bicarbonate; BUN; chloride; creatinine; potassium; lactate; heart rate; mbp; respiratory rate; temperature; spo2; glucose; sofa; sapsii. | ||||||
| Characteristic | N | NLR of 90-day mortality | ||||
| Q 1 | Q 2 | Q 3 | Q4 | P for interaction | ||
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||
| Age | 0.943 | |||||
| 1590 | 1 (Ref) | 1.37 (0.86~2.2) | 1.65 (1.04~2.62) | 1.84 (1.16~2.9) | ||
| ≥75 | 1060 | 1 (Ref) | 1.14 (0.71~1.85) | 1.57 (1~2.46) | 1.50 (0.96~2.35) | |
| Gender | 0.189 | |||||
| Female | 1227 | 1 (Ref) | 1.68 (1.01~2.79) | 1.52 (0.92~2.51) | 1.96 (1.21~3.18) | |
| Male | 1423 | 1 (Ref) | 0.99 (0.63~1.55) | 1.58 (1.04~2.4) | 1.49 (0.97~2.27) | |
| Ethnicity | 0.196 | |||||
| White | 1889 | 1 (Ref) | 1.01 (0.66~1.52) | 1.43 (0.96~2.11) | 1.42 (0.97~2.09) | |
| Non-white | 433 | 1 (Ref) | 2.13 (0.98~4.62) | 2.42 (1.07~5.47) | 2.04 (0.85~4.88) | |
| Other | 328 | 1 (Ref) | 1.22 (0.46~3.23) | 1.79 (0.71~4.56) | 2.69 (1.01~7.13) | |
| MBP | 0.027 | |||||
| 1172 | 1 (Ref) | 0.96 (0.62~1.5) | 1.01 (0.68~1.52) | 1.32 (0.9~1.95) | ||
| ≥75 | 1478 | 1 (Ref) | 2.07 (1.2~3.58) | 3.17 (1.86~5.41) | 3.12 (1.79~5.42) | |
| Malignant cancer | 0.493 | |||||
| Yes | 393 | 1 (Ref) | 0.62 (0.3~1.32) | 1.38 (0.71~2.69) | 0.94 (0.51~1.75) | |
| No | 2257 | 1 (Ref) | 1.61 (1.09~2.39) | 2.11 (1.43~3.1) | 2.54 (1.72~3.74) | |
| Congestive heart failure | 0.468 | |||||
| Yes | 1401 | 1 (Ref) | 1.1 (0.72~1.69) | 1.38 (0.91~2.1) | 1.74 (1.17~2.6) | |
| No | 1249 | 1 (Ref) | 1.55 (0.89~2.67) | 2.12 (1.27~3.53) | 2.23 (1.31~3.78) | |
| Diabetes | 0.181 | |||||
| Yes | 1024 | 1 (Ref) | 1.02 (0.62~1.69) | 1.19 (0.75~1.89) | 1.81 (1.12~2.93) | |
| No | 1626 | 1 (Ref) | 1.58 (1~2.5) | 2.02 (1.29~3.15) | 1.98 (1.27~3.08) | |
| Hypertension | 0.019 | |||||
| Yes | 841 | 1 (Ref) | 3.4 (1.44~8.04) | 2.84 (1.18~6.85) | 4.81 (2.06~11.2) | |
| No | 1809 | 1 (Ref) | 1.03 (0.71~1.5) | 1.46 (1.03~2.06) | 1.47 (1.04~2.1) | |
| Renal disease | 0.112 | |||||
| Yes | 847 | 1 (Ref) | 0.75 (0.43~1.3) | 1.08 (0.65~1.8) | 0.93 (0.56~1.55) | |
| No | 1803 | 1 (Ref) | 1.8 (1.17~2.77) | 1.91 (1.25~2.9) | 2.5 (1.65~3.78) | |
| Liver disease | 0.021 | |||||
| Yes | 327 | 1 (Ref) | 0.98 (0.44~2.18) | 1.24 (0.57~2.69) | 0.98 (0.45~2.14) | |
| No | 2323 | 1 (Ref) | 1.46 (1.01~2.12) | 1.75 (1.23~2.49) | 2.14 (1.51~3.03) | |
| HRs were adjusted for age; sex; race; diabetes; hypertension; liver disease; renal disease; malignant cancer; platelets; WBC; anion gap; bicarbonate; BUN; chloride; creatinine; potassium; lactate; heart rate; mbp; respiratory rate; temperature; spo2; glucose; sofa; sapsii. | ||||||